Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694862 | 0.83 | NOS3 (0.37) | — | |
| SCHEMBL15637783 | 0.83 | POLB (0.36) | — | |
| SCHEMBL2704513 | 0.83 | TRIM24 (0.34) | — | |
| SCHEMBL14334896 | 0.82 | SLC13A5 (0.35) | SSTR4 | |
| SCHEMBL15533093 | 0.81 | CHRM2 (0.31) | — | |
| SCHEMBL2369300 | 0.81 | L3MBTL1 (0.36) | — | |
| SCHEMBL15533151 | 0.81 | SSTR4 (0.32) | SSTR4 | |
| SCHEMBL15533639 | 0.80 | P2RX7 (0.36) | P2RX7SSTR4 | |
| SCHEMBL12098002 | 0.79 | SLC13A5 (0.39) | — | |
| SCHEMBL17845939 | 0.78 | GLO1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116231079-A | Electrolyte and preparation method and application thereof | 湖北亿纬动力有限公司 | 2023-06-06 | — | — | CN | claimed |
| EP-4729508-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12577456-B2 | Light-emitting element, light-emitting device, electronic device, lighting device, and novel organic compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| CN-119118872-A | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-116231079-B | Electrolyte and preparation method and application thereof | 湖北亿纬动力有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-12103907-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-115298165-B | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| EP-2666775-A1 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | Domain Therapeutics (FR) | 2013-11-27 | — | — | EP | disclosed |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-11-07 | — | — | US | disclosed |
| US-20130281693-A1 | Phosphorescent Organometallic Iridium Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-2614061-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2013-07-17 | — | — | EP | disclosed |
| US-20130048964-A1 | Light-Emitting Element, Light-Emitting Device, Electronic Device, Lighting Device, and Novel Organic Compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2013-02-28 | — | — | US | disclosed |
| WO-2013027846-A1 | LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE, LIGHTING DEVICE, AND NOVEL ORGANIC COMPOUND | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-02-28 | — | — | WO | disclosed |
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2012032334-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | P2RX7 2991/4885SSTR4 4144/4885 |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | P2RX7 2991/4885SSTR4 4144/4885 |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | P2RX7 3888/4885SSTR4 3778/4885 |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | P2RX7 308/4885SSTR4 553/4885 |
| US-12103907-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | HIF1AN, HIF1A, EGLN2 | P2RX7 2991/4885SSTR4 4144/4885 |
| US-12577456-B2 | Light-emitting element, light-emitting device, electronic device, lighting device, and novel organic compound | SUN2, LEF1, CTNND1 | P2RX7 26/4885SSTR4 3987/4885 |
| US-20130048964-A1 | Light-Emitting Element, Light-Emitting Device, Electronic Device, Lighting Device, and Novel Organic Compound | LAGE3, LEF1, PUM2 | P2RX7 37/4885SSTR4 4124/4885 |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | MAP3K13, MAP4K3, MAP3K3 | P2RX7 447/4885SSTR4 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.